|1.||Loh, Tze Ping: 1 article (01/2013)|
|2.||Yin, Cecilia: 1 article (01/2013)|
|3.||Sethi, Sunil K: 1 article (01/2013)|
|4.||Saw, Sharon: 1 article (01/2013)|
|5.||Prashanth, G P: 1 article (10/2011)|
|6.||Hegde, Deeparaj Ganapati: 1 article (10/2011)|
|7.||Bagalkot, Praveen S: 1 article (10/2011)|
|8.||Nicol, Kathleen: 1 article (06/2008)|
|9.||Moder, Phylis: 1 article (06/2008)|
|10.||Swedan, Nawwar: 1 article (06/2008)|
06/09/1978 - "Genetic and biosynthetic studies of families carrying hemoglobin J alpha Mexico: association of alpha-thalassemia with HbJ."
07/01/1988 - "Hemoglobin J (HbJ), Guantanamo, which had been described but once in the literature, was found in a family originating from Benin; this second case was found to be in association with hemoglobin C (HbC) and alpha-thalassemia. "
11/01/2007 - "Ten independent prognostic factors other than treatment group were identified in multivariate analysis: (a) presence of liver metastases [hazard ratio (HR), 1.66; P = 0.019], (b) number of metastatic sites (HR, 1.63 if > or =2 sites; P = 0.001), (c) clinically significant pain (HR, 1.48; P < 0.0001), (d) Karnofsky performance status (HR, 1.39 if < or =70; P = 0.016), (e) type of progression (HR, 1.37 for measurable disease progression and 1.29 for bone scan progression; P = 0.005 and 0.01, respectively), (f) pretreatment prostate-specific antigen (PSA) doubling time (HR, 1.19 if <55 days; P = 0.066), (g) PSA (HR, 1.17 per log rise; P < 0.0001), (h) tumor grade (HR, 1.18 for high grade; P = 0.069), (i) alkaline phosphatase (HR, 1.27 per log rise; P < 0.0001), and (j) hemoglobin (HR, 1.11 per unit decline; P = 0.004). "
|3.||beta-Thalassemia (Cooley's Anemia)
|3.||Prostate-Specific Antigen (Semenogelase)